Vladonix
- Category
- Bioregulators
- Administration routes
- Oral
- Regulatory status
- Not FDA-approved
What it is
A bovine thymus-derived peptide marketed to restore immune competence and slow age-related thymic decline. The case rests mostly on mechanism and animal data; human evidence is low-confidence, and claims of post-chemo recovery or lower mortality with long-term use are speculative. Chief risk is immune overstimulation in autoimmune conditions, plus low risks of allergy and prion exposure. Not FDA-approved; sold mainly as unregulated products online.
Read Full recordStudied uses & evidence
Studied uses(4)
Immune system restoration and normalization
LowBased mainly on injectable Thymalin data, not oral Vladonix, with unblinded, preliminary human reporting.
Post-radiation/chemotherapy immune recovery
SpeculativeIndirect evidence from a Vilon colorectal-cancer report indexed as a controlled clinical trial; it does not establish benefit for oral Vladonix.
Reduced mortality in long-term anti-aging protocols
SpeculativeBased on one unreplicated study of injectable peptides, not modern trial design or oral Vladonix.
Evidence limits
- Evidence Level
- Limited Evidence (with stronger data for related injectable Thymalin)
Direct evidence for Vladonix capsules is limited to Khavinson Institute reports. However, the related injectable Thymalin has decades of Russian clinical use and the most extensive published data of any Khavinson peptide, including the landmark Kiev study showing mortality reduction over 6-12 years. The PMC-indexed thymalin review (PMC8365293) provides robust molecular mechanism data. Vladonix oral capsules are extrapolated from this stronger evidence base.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(3)
Risks = level of concern: High · Moderate · Low · Theoretical
Allergic reaction to bovine thymus-derived peptides
LowPotential immune overstimulation in autoimmune conditions
ModeratePrion/BSE concerns (bovine thymus origin)
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.